Omega Therapeutics, Inc. announced a research collaboration with Novo Nordisk to develop a novel therapeutic for obesity management. The collaboration will leverage Novo Nordisk?s expertise in research and development within cardiometabolic diseases and Omega?s proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. This agreement was signed under the existing framework collaboration between Flagship Pioneering and Novo Nordisk to develop a portfolio of transformational medicines.

Omega, Flagship?s Pioneering Medicines initiative, and Novo Nordisk will jointly advance this obesity management program through preclinical development and conduct foundational activities, after which point Novo Nordisk could further advance the program including through human proof-of-concept studies. Under the terms of the agreement, Novo Nordisk will reimburse R&D costs and has the right to select one target to advance for clinical development. Omega and Pioneering Medicines are eligible to receive up to $532 million in upfront, development and commercial milestone payments, as well as tiered royalties on annual net sales of a licensed product.